About the API
Diroximel fumarate, also known as ALKS-8700, is in Phase III clinical trials for the treatment of relapsing remitting multiple sclerosis, which is the most common form of multiple sclerosis (MS). Relapsing remitting MS is characterized by episodes of worsening neurologic functioning followed by partial or complete recovery periods free of disease progression.
Orally administered twice daily, diroximel fumarate is a prodrug of monomethyl fumarate (MMF) in a controlled-release formulation. A prodrug is a medication that, following administration, is converted into a pharmacologically active drug in the body. MMF has immunomodulating and neuroprotective effects.
Diroximel fumarate was proven effective in clinical trials, and the current Phase III clinical trials are not required to test efficacy; rather, they are limited to safety and tolerability.